Immunotherapy in complex treatment of antyphospholipid syndrome
Keywords:antyphospholipid syndrome, hemostasis system, fetal loss syndrome, immunocompetent lymphocytes, intravenous immunoglobulin Bioven Mono
AbstractThe results of laboratory and clinical studies of the drug intravenous immunoglobulin (IV-Ig) Bioven Mono in the treatment of fetal loss syndrome, which is caused by antiphospholipid syndrome. In the group of pregnant women who received therapy IV-Ig, marked decrease in levels antiphospholipid antibodies, markers of thrombophilia, reducing the frequency of pregnancy complications and improve perinatal indicators. It is noted that immune-modulating effect is probably related to its positive impact on the function of T-regulatory lymphocytes.
Branch DW A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy / DW Branch., AM Peaceman, RK Silver // The Pregnancy Loss Study Group. Am J Obstet Gynecol. – 2000. – Jan. – Vol. 182 (1Pt 1). – P. 122–127.
Carp H Inravenous immunoglobulin and recurrent pregnancy loss / H Carp, T Sapir, Y Shoenfeld // Clin. Rev. Allegy Immunol. – 2005. – Vol. 29, № 3. – P. 327–332.
Coulam CD Correlation of NK cell activation and inhibition markers with NK cytoxicity among women experiencing immunologic implantation failure after in vitro ferilization and embryotransfer / CD Coulam, RG Roussev // J. Ass. Reprod. Genet. – 2003. – Vol. 20. – P. 58–62.
Guerin LR Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment? / LR Guerin // Human Reproduction Update. – 2009. – Vol. 15, № 5. – P. 535–571.
Chen ML Regulatry T-cells suppress tumor-speci£ c CD8 T-cell cytotoxity through TGF-b signals in vivo / ML Chen, MJ Pittet, I Gorelik // Proc. Nath. Acaci. Sci USA. – 2005. – Vol. 102. – P. 409–424.
Christiansen OD A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarnage evidence for a therapeutic e ect in women with secondry recurrent miscamage / OD Christiansen // Hum. Reprod. – 2002. – Vol. 17. – P. 809–816.
Shoenfeld Y IVIG therapy in autoimmunity and related disorders our experience with a large cohort of patients / Y Shoenfeld, U Kutz // Autoimmunity. – 2005. – Vol. 38, № 2. – P. 123–137.
Stricker RB Intravenous immunoglobulin therapy for immunologic abortion / RB Stricker, A Stenleitner, EE Winger // Clin. Appl. Rev. – 2002 – Vol. 43. – P. 187–199.
Stephenson M Inravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebo-controlled trial / M Stephenson // Hum. Reprod. – 2010. – Vol. 25, № 9. – P. 2203–1209.
Tzronkowski P CD4+ CD25+ T-regulatory cells ingibit human cytotoxic activity of CTL and NK-cells in humans – impact of immunosensence / P Tzronkowski, E Szit, E Mysliwska // Clin. Immunol. – 2006. – Vol. 119. – P. 307–312.
Triolo G IVIG in pregnancy / G Triolo // Lupus. – 2004. – Vol. 13, № 9. – P. 731–736.
Linnikov VI Diagnostics, principles of treatment and prevention of thrombophilic conditions associated with primary antyphospholipid syndrome in pregnancy, childbirth and postpartum women dissertation for the degree of MD. – Moscow, 2005. – P. 33–35.
Makatsaria AD Antiphospholipid syndrome – immune thrombophilia in obstetrics and gynecology // AD Makatsaria, VO Bicadze, SM Baymuratova. – Moscow: Triada-X, 2007. – P. 1112.
Sel’kov AV Methods for determination of T-regulatory cells levels in the peripheral blood / AV Sel’kov, AV Seljutin // Laboratory diagnostics. – 2008. – № 4. – P. 19–21.
Sidelnikova VM Habitual pregnancy loss / VM Sidelnikova. – Moscow: Triada-X, 2005 – P. 304–307.
Yarilin AA Dependent on factors FOXp3 regulatory T-cells, and the prospects of their study in pregnancy / AA Yarilin, FD Donetskova // Rus. J. Immunol. – 2005. – Vol. 9. – P. 149–152.
Copyright (c) 2014 В. И. Линников
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.